Ligand Reports Second Quarter 2023 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Tesla acquires AI hardware company for up to $2 billion in stock
Ligand Pharma (LGND) Tops Q2 EPS by 84c
August 8, 2023 4:53 PM EDTLigand Pharma (NASDAQ: LGND) reported Q2 EPS of $1.42, $0.84 better than the analyst estimate of $0.58. Revenue for the quarter came in at $26.4 million versus the consensus estimate of $24.74 million.
GUIDANCE:
Ligand Pharma sees FY2023 EPS of $4.85-$5.00, versus the consensus of... More
